PURPOSE: The objective of this study was to examine the metabolism and disposition of the HIV protease inhibitor lopinavir in humans and animal models. METHODS: The plasma protein binding of [14C]lopinavir was examined in vitro via equilibrium dialysis technique. The tissue distribution of radioactivity was examined in rats dosed with [14C]lopinavir in combination with ritonavir. The metabolism and disposition of [14C]lopinavir was examined in rats, dogs, and humans given alone (in rats only) or in combination with ritonavir. RESULTS: The plasma protein binding of lopinavir was high in all species (97.4-99.7% in human plasma), with a concentration-dependent decrease in binding. Radioactivity was extensively distributed into tissues, except brain, in rats. On oral dosing to rats, ritonavir was found to increase the exposure of lopinavir-derived radioactivity 13-fold. Radioactivity was primarily cleared via the hepato-biliary route in all species (>82% of radioactive dose excreted via fecal route), with urinary route of elimination being significant only in humans (10.4% of radioactive dose). Oxidative metabolites were the predominant components of excreted radioactivity. The predominant site of metabolism was found to be the carbon-4 of the cyclic urea moiety, with subsequent secondary metabolism occurring on the diphenyl core moiety. In all the three species examined, the primary component of plasma radioactivity was unchanged lopinavir (>88%) with small amounts of oxidative metabolites. CONCLUSIONS: Lopinavir was subject to extensive metabolism in vivo. Co-administered ritonavir markedly enhanced the pharmacokinetics of lopinavir-derived radioactivity in rats, probably due to inhibition of presystemic and systemic metabolism, leading to an increased exposure to this potent HIV protease inhibitor.
PURPOSE: The objective of this study was to examine the metabolism and disposition of the HIV protease inhibitor lopinavir in humans and animal models. METHODS: The plasma protein binding of [14C]lopinavir was examined in vitro via equilibrium dialysis technique. The tissue distribution of radioactivity was examined in rats dosed with [14C]lopinavir in combination with ritonavir. The metabolism and disposition of [14C]lopinavir was examined in rats, dogs, and humans given alone (in rats only) or in combination with ritonavir. RESULTS: The plasma protein binding of lopinavir was high in all species (97.4-99.7% in human plasma), with a concentration-dependent decrease in binding. Radioactivity was extensively distributed into tissues, except brain, in rats. On oral dosing to rats, ritonavir was found to increase the exposure of lopinavir-derived radioactivity 13-fold. Radioactivity was primarily cleared via the hepato-biliary route in all species (>82% of radioactive dose excreted via fecal route), with urinary route of elimination being significant only in humans (10.4% of radioactive dose). Oxidative metabolites were the predominant components of excreted radioactivity. The predominant site of metabolism was found to be the carbon-4 of the cyclic urea moiety, with subsequent secondary metabolism occurring on the diphenyl core moiety. In all the three species examined, the primary component of plasma radioactivity was unchanged lopinavir (>88%) with small amounts of oxidative metabolites. CONCLUSIONS:Lopinavir was subject to extensive metabolism in vivo. Co-administered ritonavir markedly enhanced the pharmacokinetics of lopinavir-derived radioactivity in rats, probably due to inhibition of presystemic and systemic metabolism, leading to an increased exposure to this potent HIV protease inhibitor.
Authors: J F Denissen; B A Grabowski; M K Johnson; A M Buko; D J Kempf; S B Thomas; B W Surber Journal: Drug Metab Dispos Date: 1997-04 Impact factor: 3.922
Authors: G N Kumar; J Dykstra; E M Roberts; V K Jayanti; D Hickman; J Uchic; Y Yao; B Surber; S Thomas; G R Granneman Journal: Drug Metab Dispos Date: 1999-08 Impact factor: 3.922
Authors: D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191
Authors: C Merry; M G Barry; F Mulcahy; M Ryan; J Heavey; J F Tjia; S E Gibbons; A M Breckenridge; D J Back Journal: AIDS Date: 1997-03-15 Impact factor: 4.177
Authors: N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn Journal: Science Date: 1990-04-20 Impact factor: 47.728
Authors: D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong Journal: Proc Natl Acad Sci U S A Date: 1995-03-28 Impact factor: 11.205
Authors: A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191
Authors: G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci Journal: Nature Date: 1993-03-25 Impact factor: 49.962
Authors: Laura Dickinson; Marta Boffito; David Back; Laura Else; Nils von Hentig; Geraint Davies; Saye Khoo; Anton Pozniak; Graeme Moyle; Leon Aarons Journal: Antimicrob Agents Chemother Date: 2011-03-21 Impact factor: 5.191
Authors: Sheetal Agarwal; S H S Boddu; Ritesh Jain; Swapan Samanta; Dhananjay Pal; Ashim K Mitra Journal: Int J Pharm Date: 2008-03-28 Impact factor: 5.875
Authors: Jeroen J A van Kampen; Mariska L Reedijk; Peter C Burgers; Lennard J M Dekker; Nico G Hartwig; Ineke E van der Ende; Ronald de Groot; Albert D M E Osterhaus; David M Burger; Theo M Luider; Rob A Gruters Journal: PLoS One Date: 2010-07-01 Impact factor: 3.240
Authors: Ravikiran S Yedidi; Zhigang Liu; Iulia A Kovari; Patrick M Woster; Ladislau C Kovari Journal: J Mol Graph Model Date: 2013-11-01 Impact factor: 2.518
Authors: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447